In summary, we provided further evidence on the efficacy of the CFTR modulators ELX/TEZ/IVA, adding information about their effect on respiratory muscle performance and nocturnal cardiorespiratory polygraphy parameters, which have not been investigated up to now, in CF patients with severe lung disease. The gene discussed is CFTR; the disease is cystic fibrosis.